Trump’s Second Act Could Mean Big Shifts in Federal Marijuana Policy
As the country anticipates another possible Trump administration, the cannabis industry is left wondering if marijuana legalization will see the same, slow-burn momentum it had under President Biden. The previous administration under Biden had just started loosening federal restrictions, with the cannabis sector inching closer to mainstream legitimacy. But will Trump’s return to the White House boost these reforms or reverse them? While Biden’s policy shift aimed to place marijuana in Schedule III (finally acknowledging its medical value), it’s anyone’s guess whether Trump’s administration will hold the line or rewind the progress.
With cannabis laws hanging in the balance, the implications of a new administration for federal reform, market potential, and state authority are huge. As the political rhetoric rises, it becomes evident that this crossroads could either pave the way for lasting reform or plunge the movement back into a shadow of stigma and overly cautious restrictions.
Takeaways on Trump’s Cannabis Stance
- Biden’s cannabis rescheduling aimed to open doors for medical research and state-led markets, but Trump’s return raises questions.
- Trump has voiced unexpected support for adult use and safety-focused regulations, hinting at continuity rather than reversal.
- Project 2025 prioritizes opioid and fentanyl crises, leaving cannabis reform in uncertain territory.
- States continue to lead cannabis legalization, but without federal backing, inconsistent regulations could limit growth.
- The potential for federal cannabis banking reform is huge, offering tax revenue benefits and stability, though it hinges on Trump’s priorities.
Biden’s Cannabis Steps and Their Significance
Under the Biden administration, a historic proposal was set forth: moving marijuana from a Schedule I substance to Schedule III—a shift with substantial consequences. This proposed reclassification would recognize marijuana’s medical potential, enabling it to be studied and prescribed more liberally. It would also lessen the punitive measures associated with marijuana-related charges, a significant change for federal policy that has otherwise treated cannabis like heroin or LSD. This move has ignited optimism within the cannabis industry, suggesting that the government is finally willing to reevaluate its outdated stance.
So, what does Schedule III really mean for consumers and the economy? For starters, rescheduling opens doors to increased scientific research, allowing researchers to explore its therapeutic effects without the bureaucratic maze of Schedule I regulations. This change would fuel medical research, creating potential new pathways for cannabis-based treatments. The reclassification could also attract significant investment, transforming cannabis into a legitimate market player with less of the legal risk that has hindered growth. However, it’s worth asking: Will a potential Trump administration honor this forward momentum, or will it stall progress in favor of playing to conservative fears about public safety and morality?
Trump’s Position on Cannabis
As Trump eyes another term, speculation about his stance on cannabis is swirling. His recent comments have been surprisingly supportive, signaling an openness to sensible cannabis policy. In a Truth Social post, he went as far as to say, “It is time to end needless arrests and incarcerations of adults for small amounts of marijuana for personal use.” It’s a statement that could have been pulled directly from a pro-cannabis playbook—yet it’s also the kind of talk that needs to be backed up by action, not just campaign rhetoric.
Interestingly, Trump has hinted that he might pursue a similar direction to Biden’s proposed Schedule III reclassification, which could represent a major shift in Republican priorities on cannabis. In fact, Trump has publicly aligned himself with a more permissive stance, claiming that regulation and safety should be the primary focus, not moralistic policing. This more moderate approach is likely an attempt to appeal to the growing number of Americans who support legalization, though it remains to be seen whether his actions will reflect his words.
Trump’s 2025 agenda, however, lacks any specific mention of marijuana, raising questions about whether his administration will prioritize cannabis reform or quietly sideline it in favor of other issues. It’s hard to ignore the possibility that Trump might instead get swept into the conservative-driven Project 2025, a blueprint that puts the opioid crisis and anti-drug campaigns at the forefront, effectively sidelining cannabis in favor of harsher drug enforcement. If this happens, cannabis reform may find itself, once again, an afterthought in federal policy.
Project 2025 and the Conservative Agenda
For those hoping cannabis reform will gain traction, Project 2025 introduces a chilling counterpoint. Created by conservative policymakers, Project 2025 prioritizes an aggressive stance on the fentanyl crisis and the opioid epidemic. The plan proposes a sweeping agenda to curb drug trafficking, which, in theory, could be extended to include cannabis if a hardline administration chooses to broaden its scope.
The 2025 agenda is clear: it aims to disrupt drug trafficking, bolster drug prevention, and strengthen “treatment that leads to long-term recovery.” While the document doesn’t explicitly mention marijuana, the lack of support for cannabis reform is loud and clear. Such vague, drug-war-style rhetoric may well signal a step backward, a potential return to policies that ignore the distinctions between cannabis and dangerous opioids. The conservative agenda is suspiciously quiet on cannabis, giving the impression that any reform would likely be a byproduct of other priorities, rather than a goal in itself.
Should Trump choose to support Project 2025 as it stands, the cannabis industry could face renewed challenges. And while public opinion may lean heavily in favor of legalization, the conservative base pushing Project 2025 may well sideline the cannabis industry, viewing it as an unwelcome addition to their vision of a “drug-free” America.
How a Second Trump Administration Could Affect the States
Since the federal government under Biden began to soften its cannabis stance, states have steadily marched toward legalization, and as of now, 24 states plus Washington D.C. have legalized recreational cannabis use. In states like Florida, massive campaigns (backed by big cannabis businesses like Trulieve) have been pushing for even broader legalization, despite fierce opposition from conservative lawmakers and public figures. Trump himself expressed support for Florida’s recreational cannabis ballot initiative, marking a significant departure from the “Just Say No” rhetoric of the past.
If Trump maintains a hands-off approach, the federal government may allow states to continue setting their own cannabis laws, aligning cannabis regulation with how alcohol is managed. In theory, this setup would let states maintain autonomy over marijuana policies, shielding them from federal interference and creating a patchwork of state-led regulations. However, this could also mean a lack of uniform federal standards, leaving cannabis companies scrambling to comply with a mishmash of local rules, rather than a cohesive federal framework.
Balancing Health Concerns and Market Potential
Cannabis remains a hot-button topic in the realm of public health, with voices on both sides of the debate. The Surgeon General recently sounded the alarm on the risks of marijuana addiction, highlighting concerns that the industry may downplay potential harms to public health. With more people using cannabis regularly, especially in states with legalized recreational use, there’s rising demand for more standardized research and clear, public-health-focused guidelines.
In a hypothetical Trump administration, cannabis regulation might focus on preventing underage use and maintaining rigorous testing standards—both critical for a legal market. But there is also the risk that over-cautious regulation could stymie the industry’s growth by treating cannabis as a looming public health threat, rather than a controlled, taxable product like alcohol. Such restrictions could wind up feeding the black market rather than protecting consumers, ultimately backfiring on any attempt to curb misuse.
The stakes are high: cannabis reform under a Trump administration could strike a balance between public safety and market potential, or it could veer toward suffocating regulation that hinders innovation and alienates consumers. With states continuing to lead the charge, Trump’s policies will need to match the public’s call for responsible, accessible cannabis markets.
Tax Revenue, Banking, and the Federal-State Divide
Legal cannabis has been a cash cow for states, bringing in billions in tax revenue—money that has been reinvested into public infrastructure, education, and drug treatment programs. In 2023 alone, cannabis tax revenue across the states surpassed $4 billion. Federal legalization, or at least rescheduling, could vastly expand this tax base by paving the way for uniform banking policies, allowing cannabis businesses access to safe, federally-backed financial services.
A Trump administration’s response to the cannabis banking issue could be critical. As it stands, cannabis businesses still struggle to secure basic banking services, given marijuana’s federally illegal status. If Trump were to support measures like the SAFE Banking Act, which has gained bipartisan support, the industry could see a dramatic increase in legitimacy and stability. This would enable cannabis businesses to operate in the open, boosting both state and federal tax revenue streams.
While Project 2025 doesn’t explicitly address cannabis banking, Trump could take the opportunity to support these bipartisan efforts, recognizing the financial benefits of a regulated, transparent cannabis market. By treating cannabis like alcohol—letting states lead with federal support—Trump’s administration could legitimize the industry in a way that benefits both the government and the public.
The question remains: Will Trump take cannabis reform across the finish line, or will he bury it in favor of dated, anti-drug priorities? The answer could shape the future of federal cannabis policy for decades to come.